TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05725772

Intervention type: OTHER
Intervention: Location of Visit
Description: Participants will perform visits 1) at-home via telemedicine, 2) in-person and 3) at a local regional clinic via telemedicine
Study: NCT04676724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: Participants will be administered GSK3228836.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN
Description: Participants will be administered PegIFN.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN
Description: Participants will be administered PegIFN.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA therapy
Description: Participants will continue to receive their NA therapy for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA therapy
Description: Participants will continue to receive their NA therapy for the duration of the study.
Study: NCT05979480

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray absorptiometry (DXA)
Description: DXA scan to assess bone mineral density, fat mass and muscle mass.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray absorptiometry (DXA)
Description: DXA scan to assess bone mineral density, fat mass and muscle mass.
Study: NCT04844008

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nanobubble drink
Description: Commercially available sports drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nanobubble drink
Description: Commercially available sports drink
Study: NCT05259319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]
Description: Treatment given every 21 days during 24 months or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Treatment given every 21 days during 24 months or until progression

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
Study: NCT05362149

Intervention type: DRUG
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.

Intervention type: DRUG
Intervention: Enzalutamide
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.

Intervention type: DRUG
Intervention: Apalutamide
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Study: NCT05631704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05769946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: A PDE-4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: A PDE-4 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: A PDE-4 inhibitor
Study: NCT05845203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere
Description: perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere
Study: NCT06089005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization device
Description: Application of IASTM tool on specific muscle areas twice daily for intervention protocol of 7 days
Study: NCT06046417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev
Description: Lyumjev delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev
Description: Lyumjev delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyumjev
Description: Lyumjev delivered in a basal-bolus manner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID) system
Description: The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID) system
Description: The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.
Study: NCT04794153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.
Study: NCT05762640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT.
Study: NCT06285071

Intervention type: DRUG
Intervention: Concizumab
Description: Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
Study: NCT06279195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
Description: All participants will be instructed to take REL-CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
Description: All participants will be instructed to take REL-CT.
Study: NCT00063804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD070
Study: NCT05756751

Intervention type: DEVICE
Group type: OTHER
Intervention: Device: Impella 5.5 with SmartAssist
Description: Patients who are deemed high-risk due to low preoperative ejection fraction undergoing cardiac surgery with cardiopulmonary bypass (CPB) which will be supported by the Impella 5.5 System.
Study: NCT06481943

Intervention type: DEVICE
Intervention: Sponsor MCG device (CardiAQ)
Description: Unshielded magnetocardiography device for measuring cardiac magnetic fields
Study: NCT05516771

Intervention type: DEVICE
Intervention: Tcore™ system
Description: The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers.
Study: NCT05460858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06252155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing. The mother will be told to feel comfortable, to feel her body relax from head to toe while listening to music, to focus on the music and to free her thoughts.
Study: NCT06159543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mango
Description: 1.5 cups/day of mango for 12 weeks
Study: NCT05940961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
Study: NCT06202274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
Description: Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
Study: NCT05177549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral knee examination with Lachmeter®
Description: Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral knee examination with Lachmeter®
Description: Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral knee examination with Lachmeter®
Description: Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
Study: NCT04075136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection 0.5 MG Per 0.05 ML Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection 0.5 MG Per 0.05 ML Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection 0.5 MG Per 0.05 ML Injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic laser treatment (PDT)
Description: PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic laser treatment (PDT)
Description: PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of 0.5ml-2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
Study: NCT06349915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Wellbeing with Everyday Experiences of Peers (SWEEP)
Description: Each day during a 14-day trial period, participants will receive one narrative featuring lived experience with and recovery from suicidal thoughts and behaviors. These narratives will be presented in audio and text format via a smartphone app. Participants will also complete self-report surveys assessing study outcomes using the same smartphone app five times per day.
Study: NCT06477640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention group will receive daily activity messages sent through SMS text message or email.The messages will provide daily exercises with heart rate guidance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: The control group will receive daily non-descript messages to help with blinding and to eliminate the confounding variable of daily contact. The messages will not include activity tasks and will include phrases such as I hope you have a good day.
Study: NCT05473793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried chicory root particles
Description: The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried chicory root particles
Description: The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried chicory root particles
Description: The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control arm receives a placebo consisting of rice puff particles.
Study: NCT05013632

Intervention type: DRUG
Intervention: Antiviral Agents
Description: Antiviral medications indicated for the treatment of mild to severe COVID-19

Intervention type: DRUG
Intervention: Monoclonal antibody
Description: Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
Study: NCT04794153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.
Study: NCT05471531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Description: Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Description: Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Description: Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
Study: NCT05768165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness.
Study: NCT05727189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRR (1)
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRR (1)
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRR (1)
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRR (1)
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRR (2)
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRR (3)
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRS
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRS
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XRS
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XR
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XR
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-XR
Description: Extended-release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-IR
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-01-IR
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator